Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Introduction
00:00 • 2min
The Differential Between Waldenstrom's and IgM Myeloma
01:45 • 3min
IgM, Muggis, or Waldenstrom's?
05:04 • 3min
The Importance of First-Length Therapy
07:37 • 2min
The Importance of Initiating Therapy in a Waldenstrom Patient
09:48 • 2min
How to Treat Multiple Myeloma Patients
11:21 • 3min
The Importance of Plasma Exchange for Hyperviscosity
14:34 • 3min
Retuxomam and Walden's Drums
17:13 • 2min
The Pros and Cons of Retuxomam Cyclophosphamide Dexamethone
19:15 • 2min
Zanu-Brutanib and Zannab Root Nib
21:28 • 2min
Retoxumab and the Mustang
23:46 • 4min
The Effects of BTK Inhibitors on Response Rates
27:31 • 2min
The Future of Venetoclax in Waldenstrom's
29:24 • 3min
The Role of Autologous Transplant in Waldenstrom's
32:04 • 2min
The Importance of Cryoglyphylobelemia
33:35 • 2min
The Different Types of Cryoglyphylenemia
35:16 • 2min
The Role of Retoxymab in the Treatment of IgM
37:37 • 2min
The Role of Cortisol in Neuropathy
39:13 • 2min
The Role of First Degree Relatives in Waldenstrom's Disease
40:52 • 2min
The Future of Central Nervous System Therapy
42:34 • 4min